Age: - Males and females ≥18 years of age at the time of consent Type of Participant and Disease Characteristics: - Participant must have documented diagnosis of MM per IMWG diagnostic criteria - ECOG performance status of 0 or 1. - Adequate organ and bone marrow function. For NDMM participants: - Participants on Module 1: Newly diagnosed multiple myeloma (NDMM) without prior anti- myeloma therapy (no more than 2 cycles of induction therapy before enrollment are acceptable) - For participants on Module 2: Newly diagnosed MM with a minimum of 4 cycles and a maximum of 6 cycles of induction therapy completed prior to screening - Classified as high-risk MM For Early Relapsed or Primary Refractory MM (1 or 2 prior lines of therapy) participants: - Have received and failed 1 or 2 lines of anti-myeloma therapy - Have received a proteasome inhibitor (PI) and immunomodulatory drug (IMiD) as part of their previous therapy - Have documented evidence of progressive disease based on investigator's determination of response by the IMWG criteria within 1 year of starting treatment, or on or within 6 months of completing treatment of the subject's last line of anti-myeloma therapy, or have confirmed progressive disease within 6 months prior to screening and who are subsequently determined to be refractory or non-responsive to their most recent anti-myeloma treatment regimen General

• Have received prior treatment with CAR T therapy directed at any target - Known active, or prior history of central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma - Active or history of plasma cell leukemia at the time of screening - Seropositive for human immunodeficiency virus (HIV) - Active Hepatitis B infection - Active Hepatitis C infection - Serious underlying medical condition